心房颤动患者射频消融术后利伐沙班抗凝效果观察

Patients with Atrial Fibrillation After Radiofrequency Ablation the Anticoagulant Effect of Rivaroxaban

目的观察心房颤动患者行射频消融术后患者采用利伐沙班抗凝治疗对患者的影响。方法选取2012年3月~2015年3月于我院接受射频消融术治疗的80例非瓣膜性持续性或阵发性房颤患者作为研究对象,按随机数字表法分为对照组与观察组2组,每组40例,对照组术后采用华法林抗凝治疗,观察组则应用利伐沙班治疗,比较2组术后凝血、抗凝功能的变化。结果 2组术前血红蛋白、血小板、尿素氮、谷丙转氨酶、低密度脂蛋白等指标对比差异无统计学意义（P〉0.05）;观察组术后Hb下降2例,PLT下降1例,房颤复发5例;对照组ALT上高2例,PLT下降3例,房颤复发7例,2组检测指标异常发生率及房颤复发率对比差异无统计学意义（P＆gt;0.05）;观察组出血事件发生率仅为2.5%,低于对照组的15.0%,2组出血事件发生率对比差异有统计学意义（P〈0.05）。结论在心房颤动患者射频消融术后采用利伐沙班作抗凝治疗,可降低栓塞所致出血事件发生率,提高治疗安全性。

Objective To observe the effect of rivaroxaban in the treatment of patients with atrial fibrillation after radiofrequency ablation Methods 80 patients with non-valvular persistent or paroxysmal atrial fibrillation treated by radiofrequency ablation in our hospital from March 2012 to March 2015 were selected as the research objects. According to the random number table method,the patients were divided into the control group and the observation group of 2 groups with 40 cases in each group. After operation,the control group was treated with warfarin anticoagulant therapy while the observation group was treated with rivaroxaban. The changes of postoperative test indexes were compared between the two groups. Results There was no significant differences in hemoglobin,platelet,urea nitrogen,alanine aminotransferase,low density lipoprotein and other indexes between the 2 groups before operation（ P〉0. 05）; After operation,there were 2 cases of Hb decreasing,a case of PLT decreasing and 5 cases of recurrent atrial fibrillation in the observation group,and 2 caes of ALT increasing,3 cases of PLT decreasing and 7 cases of recurrent atrial fibrillation in the control group. There were no statistically significant differences in the incidence rate of abnormal test indexes and recurrence rate of atrial fibrillation between the two groups（ P〉0. 05）; The incidence rate of bleeding in the observation group（ 2. 5%） was lower than that in the control group（ 15. 0%）（ P〈0. 05）. Conclusion The application of rivaroxaban as anticoagulant therapy for patients with atrial fibrillation after radiofrequency ablation can reduce the incidence of bleeding events induced by embolization and improve the safety of treatment.